Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC)
Phase of Trial: Phase I
Latest Information Update: 16 Dec 2016
At a glance
- Drugs Lurbinectedin (Primary) ; Capecitabine
- Indications Breast cancer; Colon cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors PharmaMar
- 02 Dec 2016 Status changed from active, no longer recruiting to completed.
- 11 Oct 2016 Results assessing safety (n=65, cut off April 2016) presented at the 41st European Society for Medical Oncology Congress.
- 05 Oct 2016 According to a PharmaMar media release, data from this study will be presented at European Society of Medical Oncology (ESMO) congress 2016